Art. 97 Directive (EU) 2001/83

In forcesince 26 Jan 2007cited 10×
1.

Member States shall ensure that there are adequate and effective methods to monitor the advertising of medicinal products. Such methods, which may be based on a system of prior vetting, shall in any event include legal provisions under which persons or organizations regarded under national law as having a legitimate interest in prohibiting any advertisement inconsistent with this Title, may take legal action against such advertisement, or bring such advertisement before an administrative authority competent either to decide on complaints or to initiate appropriate legal proceedings.

2.

Under the legal provisions referred to in paragraph 1, Member States shall confer upon the courts or administrative authorities powers enabling them, in cases where they deem such measures to be necessary, taking into account all the interests involved, and in particular the public interest:

to order the cessation of, or to institute appropriate legal proceedings for an order for the cessation of, misleading advertising, or

if misleading advertising has not yet been published but publication is imminent, to order the prohibition of, or to institute appropriate legal proceedings for an order for the prohibition of, such publication,

even without proof of actual loss or damage or of intention or negligence on the part of the advertiser.

3.

Member States shall make provision for the measures referred to in the second subparagraph to be taken under an accelerated procedure, either with interim effect or with definitive effect.

It shall be for each Member State to decide which of the two options set out in the first subparagraph to select.

4.

Member States may confer upon the courts or administrative authorities powers enabling them, with a view to eliminating the continuing effects of misleading advertising the cessation of which has been ordered by a final decision:

to require publication of that decision in full or in part and in such form as they deem adequate,

to require in addition the publication of a corrective statement.

5.

Paragraphs 1 to 4 shall not exclude the voluntary control of advertising of medicinal products by self-regulatory bodies and recourse to such bodies, if proceedings before such bodies are possible in addition to the judicial or administrative proceedings referred to in paragraph 1.

  • Judgment of the Court (Third Chamber) of 1 October 2020. A v Daniel B and Others.Decision

    Title VIII, entitled ‘Advertising’, and Title VIIIa, entitled ‘Information and advertising’ of Directive 2001/83 contain, respectively, Articles 86 to 88 and Articles 88a to 100 of that directive.

    1 Oct 2020 · 62018CJ0649

  • Judgment of the Court (Third Chamber) of 11 June 2020. ratiopharm GmbH v Novartis Consumer Health GmbH.Decision

    Title VIIIa of Directive 2001/83, entitled ‘Information and Advertising’, comprises Articles 88a to 100 thereof.

    11 Jun 2020 · 62018CJ0786

  • Judgment of the Court (Third Chamber) of 5 May 2011. Novo Nordisk AS v Ravimiamet.Decision

    … veřejnosti, dále v článcích 91 až 96 pravidla o reklamě určené zdravotnickým pracovníkům a konečně v článcích 97 až 100 směrnice 2001/83 pravidla týkající se povinností členských států a držitelů rozhodnutí o …

    5 May 2011 · 62009CJ0249

  • Judgment of the Court (Fourth Chamber) of 22 April 2010. The Queen, on the application of Association of the British Pharmaceutical IndustryDecision

    Title VIII of the directive, entitled ‘Advertising’, contains Articles 86 to 88 thereof, whereas Title VIIIa of the directive, entitled ‘Information and advertising’, contains Articles 88a to 100.

    22 Apr 2010 · 62009CJ0062

  • Judgment of the Court (Grand Chamber) of 22 December 2022. SIA 'EUROAPTIEKA' v Ministru kabinets.Decision

    Title VIII of that directive, entitled ‘Advertising’, and Title VIIIa thereof, entitled ‘Information and advertising’ contain, respectively, Articles 86 to 88 and Articles 88a to 100 of that directive.

    22 Dec 2022 · 62020CJ0530

  • Opinion of Advocate General Szpunar delivered on 9 June 2022. SIA 'EUROAPTIEKA' v Ministru kabinets.Decision

    I delivered an initial Opinion in this case on 9 December 2021, following which the oral part of the procedure was closed.

    9 Jun 2022 · 62020CC0530(01)

  • Opinion of Mr Advocate General Jääskinen delivered on 19 October 2010. Novo Nordisk AS v Ravimiamet.Decision

    A systematic analysis of Titles VIII and VIIIa of Directive 2001/83 reveals four groups of rules. Articles 86 and 87 of Directive 2001/83 contain general principles relating to all advertising, whereas the detailed rules on advertising to …

    19 Oct 2010 · 62009CC0249

  • Opinion of Advocate General Szpunar delivered on 24 October 2024. Apothekerkammer Nordrhein v DocMorris NV.Decision

    It is in those circumstances that, by order of 13 July 2023, received at the Court on 10 August 2023, the Bundesgerichtshof (Federal Court of Justice) decided to stay the proceedings and to refer the following questions to the Court of …

    24 Oct 2024 · 62023CC0517

  • Opinion of Advocate General Emiliou delivered on 2 June 2022. Comité interprofessionnel des huiles essentielles françaises (CIHEF) and OtherDecision

    The inclusion of Article 72 alone within the BPR contrasts with the choice made in Directive 2001/83, Title VIII of which is expressly devoted to advertisement and contains several provisions (Articles 86 to 100) describing in detail …

    2 Jun 2022 · 62021CC0147

  • Opinion of Mr Advocate General Jääskinen delivered on 11 February 2010. The Queen, on the application of Association of the British PharmaceDecision

    A new Title VIIIa, entitled ‘Information and Advertising’, was inserted in Directive 2001/83 by Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code …

    11 Feb 2010 · 62009CC0062